ADAPTeR: A phase II study of anti-PD1 (nivolumab) therapy as pre- and post-operative therapy in metastatic renal cell carcinoma.

Mark Stares,Samra Turajlic,Andrew Furness,Kroopa Joshi,David Nicol,Martin Gore,Lisa Pickering,Nicos Fotiadis,Steve Hazell,Aspasia Soultati,Andrew Rowan,Karen O'Meara,Karl S. Peggs,Charles Swanton,Sergio A. Quezada,James Larkin

ADAPTeR: A phase II study of anti-PD1 (nivolumab) therapy as pre- and post-operative therapy in metastatic renal cell carcinoma.

2016

Mark Stares
Samra Turajlic
Andrew Furness
Kroopa Joshi
David Nicol
Martin Gore
Lisa Pickering
Nicos Fotiadis
Steve Hazell
Aspasia Soultati
Andrew Rowan
Karen O'Meara
Karl S. Peggs
Charles Swanton
Sergio A. Quezada
James Larkin

TPS4583Background: Cytoreductive nephrectomy may be beneficial in patients with metastatic clear cell renal cell carcinoma (mccRCC). However, there are currently no standard pre-operative systemic ...

Keywords:

Nivolumab
Phases of clinical research
Pathology
Operative therapy
Oncology
Renal cell carcinoma
Internal medicine
Medicine
Adapter (computing)
Urology
in patient
anti pd1
Clear cell renal cell carcinoma
pre and post

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations